DSIP
Delta sleep-inducing peptide, delta peptide
Named for what it was supposed to do in 1977. Fifty years later there is still no randomised human trial showing it improves sleep.
Preclinical only
Not approved anywhere and never submitted for approval. Sold as research material.
What it is
DSIP is a nine amino acid peptide isolated in 1977 from the cerebral venous blood of rabbits in induced slow-wave sleep. It was named for the effect the researchers were looking for, and that name has been doing promotional work ever since.
The naming is worth pausing on. A compound called delta sleep-inducing peptide sounds like a settled finding. It is a description of the experiment that found it, not of a demonstrated effect in humans.
What half a century produced
Not much, and that is the striking part.
DSIP has been studied since the late 1970s. The literature includes animal work on sleep architecture, on stroke recovery, on stress responses and on analgesia, and some of it is genuinely interesting: a phosphorylated analogue improved sleep architecture and spatial memory in animals at high altitude, and DSIP has been reported to aid motor recovery after focal stroke in rats.
There is no randomised controlled trial in humans demonstrating that DSIP improves sleep. Not a negative one, not an equivocal one. The trial that would test the compound's own name has not been run in fifty years.
Occasionally a compound sits in that state because nobody found funding. More often it sits there because early human work was unpromising and never published, and the absence of any human sleep trial after five decades of availability is not a neutral fact.
The pharmacokinetic problem
DSIP is degraded in plasma within minutes. Whether it crosses the blood brain barrier in meaningful quantity has never been established in humans, and the more recent animal work has gone into fusion constructs and modified analogues designed specifically to solve that delivery problem.
That research direction is itself an admission: if the plain peptide reached the brain adequately, nobody would be engineering carriers for it.
Practical notes
- The name is the strongest evidence anyone cites for it. Treat it as a label from a 1977 rabbit experiment rather than a claim that survived testing.
- Paradoxical alertness is a common self-report. For a compound sold as a sleep aid, a meaningful number of users report the opposite, which is what you would expect from something with no dose-response data.
- Sleep has better-evidenced interventions. Cognitive behavioural therapy for insomnia has large randomised trials behind it. Reaching past that for an untested peptide is a strange ordering of options.
Side effects and warning signs
Commonly reported
- Injection-site irritation
- Headache
- Paradoxical alertness, reported often enough to be worth noting
- No systematic human safety dataset exists
Stop and get medical help
- Persistent insomnia is a symptom with causes worth identifying, several of them treatable and some of them serious
- Any use alongside prescribed sedatives, where no interaction data exists
Sources
From the community
Discussion for this compound concentrates in r/Peptides and r/Nootropics.
No threads cached yet.
Reddit removed unauthenticated API access, so this section is populated by a build-time script using your own API credentials. Run pnpm fetch:reddit with REDDIT_CLIENT_ID and REDDIT_CLIENT_SECRET set.